These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 15210862

  • 1. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
    Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Kohler C, Kovacs D, Discafani C, Zhang N, Wu B, Floyd B, Powell D, Berger D.
    Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.
    Berger D, Dutia M, Powell D, Wu B, Wissner A, Boschelli DH, Floyd MB, Zhang N, Torres N, Levin J, Du X, Wojciechowicz D, Discafani C, Kohler C, Kim SC, Feldberg LR, Collins K, Mallon R.
    Bioorg Med Chem Lett; 2003 Sep 15; 13(18):3031-4. PubMed ID: 12941327
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M, Tanzawa F, Iwasaki S, Inaba F, Fujiwara K, Iwadare H, Echigo T, Nakamura Y, Shibata T, Suzuki K, Yasumatsu I, Nakayama A, Sasazawa Y, Tashiro E, Imoto M, Kurakata S.
    Anticancer Drugs; 2012 Jan 15; 23(1):119-30. PubMed ID: 22008853
    [Abstract] [Full Text] [Related]

  • 4. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
    Berger DM, Dutia M, Powell D, Floyd MB, Torres N, Mallon R, Wojciechowicz D, Kim S, Feldberg L, Collins K, Chaudhary I.
    Bioorg Med Chem; 2008 Oct 15; 16(20):9202-11. PubMed ID: 18815050
    [Abstract] [Full Text] [Related]

  • 5. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E.
    Clin Cancer Res; 2007 Mar 01; 13(5):1576-83. PubMed ID: 17332304
    [Abstract] [Full Text] [Related]

  • 6. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
    VanScyoc WS, Holdgate GA, Sullivan JE, Ward WH.
    Biochemistry; 2008 Apr 29; 47(17):5017-27. PubMed ID: 18393446
    [Abstract] [Full Text] [Related]

  • 7. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
    Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, Aoki T, Shimma N, Arisawa M, Sowa Y, Poulikakos PI, Rosen N, Aoki Y, Sakai T.
    Cancer Res; 2013 Jul 01; 73(13):4050-4060. PubMed ID: 23667175
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG.
    Clin Cancer Res; 2011 Mar 01; 17(5):989-1000. PubMed ID: 21245089
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
    Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S.
    Mol Cancer Ther; 2005 Mar 01; 4(3):457-70. PubMed ID: 15767555
    [Abstract] [Full Text] [Related]

  • 16. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.
    Cancer Res; 2004 Oct 01; 64(19):7099-109. PubMed ID: 15466206
    [Abstract] [Full Text] [Related]

  • 17. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
    Wissner A, Berger DM, Boschelli DH, Floyd MB, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou HR, Upeslacis E, Wang YF, Wu B, Ye F, Zhang N.
    J Med Chem; 2000 Aug 24; 43(17):3244-56. PubMed ID: 10966743
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF.
    J Pharmacol Exp Ther; 2009 Apr 24; 329(1):360-7. PubMed ID: 19147858
    [Abstract] [Full Text] [Related]

  • 19. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
    Romerio F, Riva A, Zella D.
    Br J Cancer; 2000 Aug 24; 83(4):532-8. PubMed ID: 10945503
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.